日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types

对多种肿瘤类型中 PD-L1 IHC 28-8 和 22C3 pharmDx 检测的实际应用、周转时间和分析一致性进行分析

期刊:Journal of Clinical Pathology
影响因子:2
doi:10.1136/jclinpath-2020-206466
Krigsfeld, Gabriel S; Prince, Emily A; Pratt, James; Chizhevsky, Vladislav; William Ragheb, Josette; Novotny, James Jr; Huron, David
PD-L1
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma

开发用于诊断黑色素瘤纳武利尤单抗治疗的程序性死亡受体1配体1免疫组化检测方法

期刊:
影响因子:
doi:10.1097/PAI.0000000000000605
Phillips, Therese; Millett, Molly M; Zhang, Xiaoling; Jansson, Malinka; Cleveland, Rachel; Simmons, Pauline; Cherryholmes, Gregory; Carnahan, Josette; William, Josette; Spaulding, Betsy; Satnick, Ilana R; Inzunza, H David; Taylor, Clive; Cogswell, John; Novotny, James; Oroudjev, Emin; Winther, Henrik
黑色素瘤
信号转导
IHC
免疫/内分泌
发表日期：2018
文献求助 收藏

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.

Dako 28-8 PharmDx 检测与 E1L3N 实验室开发的检测在程序性死亡配体 1 的免疫组织化学检测中的分析比较

期刊:Molecular Diagnosis & Therapy
影响因子:4.4
doi:10.1007/s40291-016-0237-9
Cogswell John, Inzunza H David, Wu Qiuyan, Feder John N, Mintier Gabe, Novotny James, Cardona Diana M
免疫/内分泌
发表日期：2017
文献求助 收藏